Public Health and Disease Prevention
Authorisation of COVID-19 Vaccines under the Prevention and Control of Disease (Use of Vaccines) Regulation (Cap.599K)
Report on Evaluation by Advisory Panel on COVID-19 Vaccines
Brief summary update on COVID-19 Vaccines endorsed by Advisory Panel
- Brief Summary Update on CoronaVac COVID-19 Vaccine (Vero Cell), Inactivated (4 July 2023)
(135KB) - Brief Summary Update on CoronaVac COVID-19 Vaccine (Vero Cell), Inactivated (15 February 2023)(28KB)
- Brief Summary Update on CoronaVac COVID-19 Vaccine (Vero Cell), Inactivated (19 September 2022)(27KB)
- Brief Summary Update on CoronaVac COVID-19 Vaccine (Vero Cell), Inactivated (7 July 2022)(144KB)
- Brief Summary Update on CoronaVac COVID-19 Vaccine (Vero Cell), Inactivated (14 April 2022)(23KB)
- Brief Summary Update on CoronaVac COVID-19 Vaccine (Vero Cell), Inactivated (12 January 2022)(23KB)
- Brief Summary Update on CoronaVac COVID-19 Vaccine (Vero Cell), Inactivated (30 September 2021)(72KB)
- Brief Summary Update on CoronaVac COVID-19 Vaccine (Vero Cell), Inactivated (14 July 2021)(22KB)
- Brief Summary Update on CoronaVac COVID-19 Vaccine (Vero Cell), Inactivated (29 April 2021)(351KB)
- Brief Summary Update on COMIRNATY™ COVID-19 mRNA Vaccine (BNT162b2) Concentrate for Dispersion for Injection (4 July 2023)(140KB)
- Brief Summary Update on COMIRNATY™ COVID-19 mRNA Vaccine (BNT162b2) Concentrate for Dispersion for Injection (15 February 2023)(43KB)
- Brief Summary Update on COMIRNATY™ COVID-19 mRNA Vaccine (BNT162b2) Concentrate for Dispersion for Injection (19 September 2022)(24KB)
- Brief Summary Update on COMIRNATY™ COVID-19 mRNA Vaccine (BNT162b2) Concentrate for Dispersion for Injection (7 Jul 2022)(144KB)
- Brief Summary Update on COMIRNATY™ COVID-19 mRNA Vaccine (BNT162b2) Concentrate for Dispersion for Injection (14 April 2022)(23KB)
- Brief Summary Update on COMIRNATY™ COVID-19 mRNA Vaccine (BNT162b2) Concentrate for Dispersion for Injection (12 January 2022)(23KB)
- Brief Summary Update on COMIRNATY™ COVID-19 mRNA Vaccine (BNT162b2) Concentrate for Dispersion for Injection (30 September 2021)(23KB)
- Brief Summary Update on COMIRNATY™ COVID-19 mRNA Vaccine (BNT162b2) Concentrate for Dispersion for Injection (14 July 2021)(38KB)
- Brief Summary Update on COMIRNATY™ COVID-19 mRNA Vaccine (BNT162b2) Concentrate for Dispersion for Injection (29 April 2021)(385KB)
Package insert
- COMIRNATY™ COVID-19 mRNA Vaccine (BNT162b2) (Approved on 21 December 2023)(651KB)
- COMIRNATY™ Original/Omicron BA.4-5 COVID-19 mRNA Vaccine (nucleoside modified) (Approved on 21 December 2023)(661KB)
- COMIRNATY™ 3 micrograms/dose COVID-19 mRNA Vaccine (nucleoside modified) (Approved on 21 December 2023)(162KB)
- COMIRNATY™ 10 micrograms/dose COVID-19 mRNA Vaccine (nucleoside modified) (Approved on 21 December 2023)(810KB)
- CoronaVac COVID-19 Vaccine (Vero Cell), Inactivated (Approved on 2 March 2023)(248KB)
- CoronaVac COVID-19 Vaccine (Vero Cell), Inactivated (detailed edition) (Approved on 2 March 2023) (309KB)
Package Leaflet: Information for the user
- COMIRNATY™ COVID-19 mRNA Vaccine (BNT162b2) (Approved on 21 December 2023)(517KB)
- COMIRNATY™ Original/Omicron BA.4-5 COVID-19 mRNA Vaccine (Approved on 21 December 2023)(661KB)
- COMIRNATY™ 3 micrograms/dose COVID-19 mRNA Vaccine (BNT162b2) (Approved on 21 December 2023)(162KB)
- COMIRNATY™ 10 micrograms/dose COVID-19 mRNA Vaccine (BNT162b2) (Approved on 21 December 2023)(248KB)